Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00925652 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT00925652 is a Phase 2 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 55 participants.
The verdict
NCT00925652, a Phase 2 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
If residual breast cancer is found in the breast or lymph node tissue removed after preoperative chemotherapy, one may be at increased risk of breast cancer recurrence in the future. The purpose of this research study is to determine if having additional treatment after preoperative chemotherapy and surgery with bevacizumab and metronomic chemotherapy would make a difference in reducing the participants chance of breast cancer recurrence compared to the standard of care, which is observation alone. This study will also evaluate the potential additional benefits from participating in an exercise and dietary intervention compared to the dietary intervention alone. Because no one knows which which post-neoadjuvant strategy is best, participants will be "randomized" to one of the study groups: 1. Diet Intervention arm, 2. Diet and Exercise Intervention Arm, 3. Bevacizumab, cyclophosphamide, methotrexate and diet intervention, 4. Bevacizumab, cyclophosphamide, methotrexate, diet and exercise intervention arm.
Interventions
- DRUG Cyclophosphamide
- DRUG Bevacizumab
- DRUG Methotrexate
- BEHAVIORAL Lifestyle: Diet
- BEHAVIORAL Lifestyle: Diet+Exercise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2010-09 |
| Est. Completion | 2019-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00925652
The ClinicalTrials.gov registry entry for NCT00925652 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00925652 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00925652 about?
NCT00925652 is a clinical study titled "Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer". If residual breast cancer is found in the breast or lymph node tissue removed after preoperative chemotherapy, one may be at increased risk of breast cancer recurrence in the future. The purpose of this research study is to determine if having additional treatment after preoperative chemotherapy and...
What is the current status of trial NCT00925652?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2010-09. Estimated completion is 2019-01-30.
What interventions are being tested in trial NCT00925652?
The interventions under investigation include: Cyclophosphamide (DRUG), Bevacizumab (DRUG), Methotrexate (DRUG), Lifestyle: Diet (BEHAVIORAL), Lifestyle: Diet+Exercise (BEHAVIORAL).
Who is sponsoring clinical trial NCT00925652?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.